Stefano Cascinu

55PUBLICATIONS
157CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersCancer geneticsCancer diagnosis
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (55)

|Aug 12, 2026
Outcomes of Cisplatin, Gemcitabine, and Durvalumab According to TOPAZ-1 Study Eligibility: A Large Global Analysis in a Real-World Setting.

|Jul 29, 2026
Exploring the Role of Surgery After Systemic Therapy in Locally Advanced Biliary Tract Cancer: Outcomes From a Large Retrospective Multinational Real-World Cohort Treated With Cisplatin, Gemcitabine, and Durvalumab.

|Jul 24, 2026
Prognostic Impact of Concomitant Genomic Alterations in FGFR2-Positive Cholangiocarcinoma Treated With Pemigatinib.

|Jun 26, 2025
D-lactate and glycerol as potential biomarkers of sorafenib activity in hepatocellular carcinoma.

Silvia Pedretti, Francesca Palermo, Miriana Braghin

|Jun 23, 2025
Comparative Effectiveness of Atezolizumab Plus Bevacizumab Versus Tremelimumab Plus Durvalumab in Patients with Hepatocellular Carcinoma (HCC) in a Real-World Setting.

Federica Lo Prinzi, Federico Rossari, Marianna Silletta

|May 19, 2025
Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real-world results from a multicenter and multinational study.

Margherita Rimini, Lorenzo Fornaro, Federica Lo Prinzi

Pageof 10

Frequent Collaborators

8 joint publications

Giorgia Marisi

8 joint publications

Margherita Rimini

6 joint publications

Caterina Vivaldi

5 joint publications

Ilario Giovanni Rapposelli